Inclusion Criteria:

• Is a healthy male or nonpregnant female (as indicated by a negative urine or serum pregnancy test immediately prior to vaccine administration) aged greater than or equal to 18 years to less than 65 years at the time of informed consent.
• Provides written informed consent to participate in the study and adherence to all protocol requirements.
• Is in good health, as determined by vital signs (heart rate, blood pressure, oral temperature), medical history, and a targeted physical examination based on medical history.
• Is able to understand and comply with planned study procedures.
• Is female of nonchildbearing potential, ie, either surgically sterilized or 1 year postmenopausal. If female is of child bearing potential, she must be abstinent or using adequate contraceptive precautions, eg, intrauterine device, oral contraceptive, or equivalent hormonal contraception (eg, progestogen-only implant, cutaneous hormonal patch, injectable contraceptives, or diaphragm) and agree to continue such precautions for 2 months after vaccination.

Exclusion Criteria:

• Known hypersensitivity to a previous dose of influenza vaccine or allergy to eggs, chicken feathers, neomycin, polymyxin, thimerosal, or any components of the study vaccines.
• Has been vaccinated against influenza in the previous 6 months.
• Has underlying medical condition for which influenza vaccination is recommended; chronic heart or lung condition including asthma; metabolic disease; kidney disease; blood disorder (such as sickle cell anemia); or weakened immune system including HIV/AIDS.
• Has acute clinically significant pulmonary, cardiovascular, hepatic, or renal functional abnormality.
• Has known history of Guillain-Barré Syndrome.
• Has clinical signs of active infection and/or an oral temperature of greater than or equal to 38°C (100.4°F). Study entry may be deferred for such individuals at the discretion of the Principal Investigator (PI).
• Has history of neurological disorders or seizures, with exception of a single febrile seizure during childhood.
• Has confirmed or suspected immunosuppressive condition (including cancer), or a previously diagnosed immunodeficiency disorder (congenital or acquired).
• Currently receiving (within the 90 days before receiving the study vaccines) immunosuppressive or immunomodulative therapy, systemic corticosteroids, and including the following medications:
• Chronic or long-term corticosteroids: greater than 15mg/day of oral prednisolone or equivalent daily;
• Sporadic corticosteroids: greater than 40mg/day of oral prednisolone or equivalent for more than 2 courses of greater than 14 days in the 3 months preceding vaccination;
• Administration of immunoglobulins and/or any blood products within the 3 months preceding the administration of the study vaccine or during the study.

Note: Use of topical or inhalant corticosteroids prior to administration of the study vaccines or throughout the study is acceptable.

• Participated in a clinical trial or use of an investigational compound within 30 days before receiving the study vaccine or plans to enter a study during the study period.
• Was vaccinated with a registered vaccine within 14 days (for inactivated vaccines) or 28 days (for live vaccines) prior to receiving the study vaccine.
• Currently treated with cytotoxic drugs or at any time during the 6 months before administration of the study vaccines.
• Has major congenital defects or serious chronic illness.
• Has evidence or history of (within the previous 12 months) drug or alcohol abuse.
• Is unwilling or unable to comply with the study protocol.
• Has a history of psychiatric disorders that, in the opinion of the PI, would prevent the subject from giving proper informed consent or otherwise interfere with the study.
• Is a resident of nursing home or long-term care facility.
• Has any condition that, in the opinion of the PI, would prevent the subject from complying with all aspects of the protocol or will put the subject at unnecessary risk.